Lonza reports softer performance in Q1 2024
Outlook 2024 remains flat CER sales growth and CORE EBITDA margin of high 20s
Outlook 2024 remains flat CER sales growth and CORE EBITDA margin of high 20s
EBITDA before special items falls 1.3 percent to € 4.41 billion
Investing considerably in production capacity for medical device packaging at its Rohrdorf and Halle sites in Germany
Sanofi India has reported total income of Rs. 738.9 crores during the period ended March 31, 2024
Lupin updates on shipment of Mirabegron ER Tablets
Novartis India has reported total income of Rs. 91.59 crores during the period ended March 31, 2024
The company has posted net profit of Rs. 4,121.55 crores for the Financial Year ended March 31, 2024
The company has posted net profit of Rs.357.7 crores for the Financial Year ended March 31, 2024
The company has posted net profit) of Rs.18.88 crores for the Financial Year ended March 31, 2024
Sevelamer Carbonate Tablets approval consolidates the company's position in the Sevelamer segment
Subscribe To Our Newsletter & Stay Updated